Regen Biopharma pays a Notavailable dividend of $0.11 which represents an annual dividend yield of N/A. See more information on Regen Biopharma dividends here
What is Regen Biopharma’s EPS estimate?
Regen Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regen Biopharma have?
Regen Biopharma has 4,114,622 shares outstanding.
What happened to Regen Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regen Biopharma?
Currently, no hedge funds are holding shares in RGBP
Regen Biopharma, Inc. engages in the development of regenerative medical applications licensed from other companies. It focuses on the immunology and immonutherapy research for the areas of Hematopoiesis, Breast Cancer, Liver Cancer, Leukemia, Myelodysplastic Syndrome, and Aplastic Anemia. The company was founded on April 24, 2012 and is headquartered in La Mesa, CA.